Endocrine Abstracts

Introduction: Several previous studies showed a reduced quality of life (QoL) in patients with Addison`s disease, but only few data on the potential influencing factors are available so far.Methods: We determined current QoL in 200 patients with Addison`s disease using AddiQoL-36, a questionnaire developed in collaboration with the European consortium Euradrenal. Furthermore, data about symptoms, diagnosis and medication were collected by questionnaires ...

Activating mutations in the gene encoding β-catenin have been identified in the paediatric form of human craniopharyngioma (adamantinomatous craniopharyngioma, ACP), an aggressive pituitary tumour accounting for up to 10% of paediatric intracranial tumours. Recently, we generated an ACP mouse model and revealed that, as in human ACP, nucleocytoplasmic accumulation of β-catenin (βcat-nc) and over-activation of the Wnt/β-catenin pathway occurs only in very fe...

Introduction: Papillary Thyroid cancer (PTC) accounts for 80% or more of all thyroid malignancies and genetic alterations associated with the development and progresion of this type of carcinoma remains largely unknown. Chromosomal band 11q13 seems to be one of the most frequently amplified regions in human cancer. Allelic imbalance involving EMSY, CAPN5 and PAK1 loci in thyroid cancer, have never been investigated. The aim of our study was to investigate the existence of alle...

A 49 years old male patient with 12 years history of poorly controlled type 2 diabetes mellitus on insulin therapy, complicated with neuropathy, nephropathy, retinopathy, peripheral arterial disease (right toe amputation), hypertension and dyslipidemia. He presented with upper extremities proximal muscle and upper back moderate pain that progressed to excruciating pain with restriction of motion, weakness, and stiffness of 3 days of evolution. He denied trauma, abnormal exerci...

Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study...

Pancreatic neuroendocrine tumors (panNETs) are the second most common neoplasm of the pancreas. panNETs arise from cells of the pancreatic islets and comprise a diverse and heterogeneous group of neoplasms. This hampers their systematic study, and the identification of common molecular signatures that might facilitate a better diagnosis of the disease, and the development of efficient therapeutic approaches. Indeed, there are no clinical, biochemical, anatomopathological, immu...